Table 3.
Comparison between laboratory parameters before and after end of treatment in patients with comorbidities
| Laboratory investigations | Group of patients with comorbidities | Test of significance | p value | |
|---|---|---|---|---|
| Pretreatment (n = 26) | End of treatment (n = 26) | |||
| TLC (k/μL), median (IQ) | 7.25(5.50–9.45) | 7.3 (5.27–9.10) | Z = 0.350 | 0.726 |
| HB (g/dL), mean ± SD | 11.75 ± 2.21 | 11.87 ± 2.66 | t = 0.469 | 0.643 |
| Plt (k/μL), median (IQ) | 294.5 (220.25–294.5) | 260 (218.5–327) | Z = 2.07 | 0.038* |
| ALT (U/mL), median (IQ) | 37.5 (29.75–57) | 19.50 (17–21.50) | Z = 3.59 | < 0.001* |
| AST (U/mL), median (IQ) | 31.5 (26.75–60) | 23.5 (18–28.5) | Z = 4.08 | < 0.001* |
| Albumin (gm/dL), mean ± SD | 4.75 ± 0.86 | 4.46 ± 0.65 | t = 1.89 | 0.070 |
| TSB (mg/dL), median (IQ) | 0.60 (0.50–0.72) | 0.90 (0.77–1) | Z = 2.17 | 0.03* |
| INR, mean ± SD | 1.06 ± 0.08 | 1.03 ± 0.08 | t = 1.10 | 0.282 |
| Cr (mg/dL), mean ± SD | 0.78 ± 0.17 | 0.74 ± 0.25 | t = 0.881 | 0.387 |
| RBG (mg/dL), median (IQ) | 90.50 (75.50–98.25) | 84 (72.75–90) | Z = 1.98 | 0.058 |
ALT alanine aminotransferase, AST aspartate aminotransferase, Cr creatinine, HB hemoglobin, INR international normalized ratio, IQ interquartile (1st Q–3rd Q), Plt platelets, RBG random blood sugar, t paired t-test, TLC total leucocytic count, TSB total serum bilirubin, Z Wilcoxon signed rank test
*Significant p ≤ 0.05